Detecting likely germline variants during tumor-based molecular profiling

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Background:

• Molecular profiling using next-generation sequencing (NGS) is integral to cancer diagnosis, prognosis, and treatment.
• NGS tumor profiling, while designed for somatic variants, frequently identifies germline DNA alterations.
• Traditional germline risk assessment relies on clinical factors, but incidental findings from NGS are increasing.

Purpose of the Study:

• To review the nuances of identifying potential germline DNA variants during NGS tumor profiling.
• To highlight differences between germline and tumor-based profiling platforms, sample types, and methodologies.
• To guide clinicians in optimizing testing strategies for germline cancer risk in the era of precision oncology.

Main Methods:

• Review of current literature and clinical guidelines on germline variant identification in tumor profiling.
• Comparative analysis of comprehensive germline testing versus tumor-based profiling platforms.
• Discussion of analytical methodologies and sample type considerations.

Main Results:

• NGS tumor profiling incidentally identifies germline alterations with increasing frequency.
• Pathogenic/likely pathogenic germline variants are key biomarkers for risk stratification and treatment.
• Expanded consensus guidelines recommend comprehensive germline testing for more cancer patients.

Conclusions:

• Clinicians must understand the distinctions between germline and tumor-based profiling to interpret incidental findings.
• Optimizing testing strategies leverages insights for germline cancer risk surveillance and management.
• Precision oncology necessitates adept navigation of germline variant data for all cancer patients.